PDF herunterladen
Horm Metab Res 2019; 51(12): 805-811
DOI: 10.1055/a-1041-3305
Endocrine Research

Lung Based Engineered Micro-Pancreas Sustains Human Beta Cell Survival and Functionality

Orit Goldman
1   Betalin Therapeutics LTD, Jerusalem Bio-Park, Jerusalem, Israel
,
Dmitry Puchinsky
1   Betalin Therapeutics LTD, Jerusalem Bio-Park, Jerusalem, Israel
,
Karina Durlacher
1   Betalin Therapeutics LTD, Jerusalem Bio-Park, Jerusalem, Israel
,
Rocio Sancho
2   Centre for Stem Cells and Regenerative Medicine, King’s College London, London, UK
3   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
,
Barbara Ludwig
3   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
4   Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Hospital Carl Gustav Carus of Technische Universität Dresden and German Centre for Diabetes Research, Dresden, Germany
5   Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
,
Patrick Kugelmeier
6   Kugelmeiers Ltd, Erlenbach, Switzerland
,
Carolin Heller
3   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
4   Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Hospital Carl Gustav Carus of Technische Universität Dresden and German Centre for Diabetes Research, Dresden, Germany
5   Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
,
Nikolai Kunicher
1   Betalin Therapeutics LTD, Jerusalem Bio-Park, Jerusalem, Israel
,
Stefan R. Bornstein
3   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
4   Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Hospital Carl Gustav Carus of Technische Universität Dresden and German Centre for Diabetes Research, Dresden, Germany
5   Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
7   Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, UK
8   Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, University Hospital, Zürich, Switzerland
,
Avraham J. Treves
1   Betalin Therapeutics LTD, Jerusalem Bio-Park, Jerusalem, Israel
› Institutsangaben Acknowledgements: This work was supported by the Deutsche Forschungsgemeinschaft (GRK 2251/1, TRR 205/1, TRR 127), the Transcampus and Transcellerator.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

The whole world has been affected by a dramatically increasing prevalence of diabetes. Today, the etiology of both type 1 and type 2 diabetes is thought to revolve around the dysfunction of β-cells, the insulin producing cells of the body. Within the pharmaceutical industry, the evaluation of new drugs for diabetes treatment is mostly done using cell lines or rodent islets and depends solely on the assessment of static insulin secretion. However, the use of cell lines or rodent islets is limiting lack of similarity of the human islet cells, leading to a constrain of the predictive value regarding the clinical potential of newly developed drugs. To overcome this issue, we developed an Engineered Micro-Pancreas as a unique platform for drug discovery. The Engineered Micro Pancreas is composed of (i) an organ-derived micro-scaffold, specifically a decellularized porcine lung-derived micro-scaffold and (ii) cadaveric islets seeded thereon. The Engineered Micro Pancreas remained viable and maintained insulin secretion in vitro for up to three months. The quantities of insulin were comparable to those secreted by freshly isolated human islets and therefore hold the potential for real-time and metabolic physiology mimicking drug screening.

Key words

human islets - engineered micro pancreas - drug development - scaffold - micro-organ-matrix


Publikationsverlauf

Eingereicht: 01. Oktober 2019

Angenommen: 30. Oktober 2019

Artikel online veröffentlicht:
11. Dezember 2019

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002–2030. PLoS Med 2006; 3: 2011-2030
    CrossrefPubMedGoogle Scholar
  • 2 Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229
    CrossrefPubMedGoogle Scholar
  • 3 Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: The last ten years. Cell 2012; 148: 1160-1171
    CrossrefPubMedGoogle Scholar
  • 4 Sionov RV, Finesilver G, Sapozhnikov L. et al. Beta cells secrete significant and regulated levels of insulin for long periods when seeded onto acellular micro-scaffolds. Tissue Eng Part A 2015; 21: 2691-2702
    CrossrefPubMedGoogle Scholar
  • 5 Abualhassan N, Sapozhnikov L, Pawlick RL. et al. Lung derived microscaffolds facilitate diabetes reversal after mouse and human intraperitoneal islet transplantation. PLoS One 2016; 11: 3156053
    CrossrefPubMedGoogle Scholar
  • 6 Ricordi C, Lacy PE, Finke EH. et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413-420
    CrossrefPubMedGoogle Scholar
  • 7 Kragl M, Lammert E. Basement membrane in pancreatic islet function. Adv Exp Med Bio 2010; 654: 217-234
    CrossrefPubMedGoogle Scholar
  • 8 Song JJ, Ott HC. Organ engineering based in decellularized matrix scaffolds. Trends Mol Med 2011; 17: 424-432
    CrossrefPubMedGoogle Scholar
  • 9 Giraldo JA, Weaver JD, Stabler CL. Enhancing clinical islet transplantation through tissue engineering strategies. J Diabetes Sci Techno 2010; 4: 1238-1247
    CrossrefPubMedGoogle Scholar
  • 10 Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: Relevance to scaffold design and transplantation. Cell Transplantation 2009; 18: 1-12
    CrossrefPubMedGoogle Scholar
  • 11 Cheng JY, Raghunath M, Whitelock J. et al. Matrix components and scaffolds for substained islet function. Tissue ENg Part B 2011; 17: 235-247
    CrossrefPubMedGoogle Scholar
  • 12 Huang G, Greenspan DS. ECM roles in the function of metabolic tissues. Trends Endocrinol Metab 2012; 23: 16-22
    CrossrefPubMedGoogle Scholar
  • 13 Brissova M, Fowler MJ, Nicholson WE. et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53: 1087-1097
    CrossrefPubMedGoogle Scholar
  • 14 Cabrera O, Berman DM, Kenyon NS. et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006; 103: 2334-2339
    CrossrefPubMedGoogle Scholar
  • 15 Braun M, Ramracheya R, Bengtsson M. et al. Voltage-gated ion channels in human pancreatic beta-cells: Electrophysiological characterization and role in insulin secretion. Diabetes 2008; 57: 1618-1628
    CrossrefPubMedGoogle Scholar
  • 16 Henquin JC, Dufrane D, Menquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes 2006; 55: 3470-3477
    CrossrefPubMedGoogle Scholar
  • 17 Rezania A, Bruin JE, Arora P. et al. Reversal of diabetes with insulin producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014; 32: 1121-1133
    CrossrefPubMedGoogle Scholar
  • 18 Pagliuca FW, Millman JR, Gurtler M. et al. Generation of functional human pancreatic B cells in vitro. Cell 2014; 159: 428-439
    CrossrefPubMedGoogle Scholar